ESSA Pharma
EPIX
EPIX was delisted on the 8th of October, 2025.
31 hedge funds and large institutions have $229M invested in ESSA Pharma in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 9 closing their positions.
124% more call options, than puts
Call options by funds: $360K | Put options by funds: $161K
122% more capital invested
Capital invested by funds: $103M → $229M (+$126M)
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
2.88% more ownership
Funds ownership: 75.89% → 78.78% (+2.9%)
14% less funds holding
Funds holding: 36 → 31 (-5)
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$11.3M |
| 2 |
Janus Henderson Group
London,
|
+$5.37M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.27M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$460K |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$200K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$4.61M |
| 2 |
O
OrbiMed
New York
|
-$2.6M |
| 3 |
Millennium Management
New York
|
-$1.46M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$472K |
| 5 |
CCM
Connective Capital Management
Palo Alto,
California
|
-$261K |
EPIX Hedge Fund Activity: Q4 2023 in Review
31 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q4 2023, worth a combined $229M — up 122% from $103M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of EPIX and 4 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 10 added.
The largest buyer was RTW Investments, opening a new position worth an estimated $11.3M. The largest seller was PFM Health Sciences, cutting an estimated $4.61M.
- 31 institutional investors held ESSA Pharma (EPIX) as of Q4 2023, down from 36 in Q3 2023.
- Funds reported $229M of ESSA Pharma stock for Q4 2023, up 122% quarter-over-quarter.
- 4 funds opened new ESSA Pharma positions in Q4 2023 and 9 closed out, a net change of -5 holders.
- The largest ESSA Pharma buyer in Q4 2023 was RTW Investments, an estimated $11.3M added.
- The largest ESSA Pharma seller in Q4 2023 was PFM Health Sciences, an estimated $4.61M sold.
Based on aggregated 13F filings for Q4 2023.